See the DrugPatentWatch profile for Turalio
Turalio, also known as pexidartinib, is a medication used to treat tenosynovial giant cell tumor (TGCT) [1]. This drug is a tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF1R) [2].
What is the status of Turalio?
Turalio received U.S. Food and Drug Administration (FDA) approval in November 2019 for adult patients with symptomatic TGCT that requires systemic treatment and is not amenable to surgical resection [1].
What are the risks associated with Turalio?
Turalio carries a risk of serious liver injury [1]. Patients taking Turalio should be monitored for liver enzyme elevations [1]. The drug is available through a restricted distribution program, the Turalio REMS (Risk Evaluation and Mitigation Strategy), to mitigate this risk [1].
How does Turalio work for TGCT?
Tenosynovial giant cell tumor is characterized by the overexpression of CSF1, which recruits CSF1R-bearing cells, leading to tumor growth [2]. Turalio inhibits CSF1R, thereby reducing the number of tumor-associated macrophages and suppressing tumor proliferation [2].
When does Turalio's patent expire?
Information on Turalio's patent expiry is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Turalio [3].
What are the alternatives to Turalio for TGCT?
Currently, Turalio is the only FDA-approved systemic therapy for TGCT [1]. Surgical resection is an option for amenable tumors, but Turalio is indicated for cases where surgery is not feasible [1].
What clinical data supports Turalio's use?
Turalio's approval was based on the ENLIVEN study, a Phase 3 trial that demonstrated significant tumor shrinkage and improvement in patient-reported outcomes in adults with symptomatic TGCT [2].
What are the common side effects of Turalio?
Common side effects of Turalio include hair color changes, fatigue, nausea, and diarrhea [1]. As noted, liver injury is a serious, albeit less common, side effect [1].
Where can I find more information about Turalio's patent status?
DrugPatentWatch.com provides detailed information on drug patents, including those for Turalio [3].
---
Sources
1. https://www.drugs.com/turalio.html
2. https://www.fda.gov/drugs/drug-approvals/turalio-pexidartinib-approval-letter
3. https://drugpatentwatch.com/